Analyst Price Target is $47.11
▲ +35.10% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Pliant Therapeutics in the last 3 months. The average price target is $47.11, with a high forecast of $55.00 and a low forecast of $33.00. The average price target represents a 35.10% upside from the last price of $34.87.
Current Consensus is
Buy
The current consensus among 9 investment analysts is to buy stock in Pliant Therapeutics. This Buy consensus rating has held steady for over two years.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Read More